Personal information

Pharmacology, Cystic Fibrosis, CFTR modulators

Activities

Works (4)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Pharmacology Research & Perspectives
2022-12 | Journal article
Part of ISSN: 2052-1707
Part of ISSN: 2052-1707
Contributors: Renate Kos; Anne H. Neerincx; Dominic W. Fenn; Paul Brinkman; Rianne Lub; Steffie E. M. Vonk; Jolt Roukema; Monique H. Reijers; Suzanne W. J. Terheggen‐Lagro; Josje Altenburg et al.
Source: Self-asserted source
Steffie Vonk

Tobramycin and vestibulotoxicity: retrospective analysis of four cases

European Journal of Hospital Pharmacy
2022-03 | Journal article
Contributors: S E M Vonk; E J M Weersink; C J Majoor; E M Kemper
Source: check_circle
Crossref

No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report

Journal of Cystic Fibrosis
2022-01 | Journal article
Contributors: S.E.M. Vonk; S.W.J. Terheggen-Lagro; L.M. Mouissie; R.A.A. Mathôt; E.M. Kemper
Source: check_circle
Crossref

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability

Therapeutic Drug Monitoring
2021-08 | Journal article
Part of ISSN: 0163-4356
Contributors: Steffie E. M. Vonk; Marloes van der Meer-Vos; Lieuwe D. J. Bos; Anne H. Neerincx; Christof J. Majoor; Anke-Hilse Maitland-van der Zee; Ron A. A. Mathôt; E. Marleen Kemper
Source: Self-asserted source
Steffie Vonk